The University of Edinburgh
Preclinical investigation of the novel SRC inhibitor eCF506 in cancer
Abstract
dc:description.abstractThe non-receptor tyrosine kinase SRC plays an important and context-dependent role in a variety of cell signalling pathways that regulate cell motility, survival, division and growth factor signalling. SRC activity has been closely linked to several hallmarks of cancer (cell proliferation, metastasis, angiogenesis) and treatment resistance. Multiple studies found SRC to be aberrantly activated and/or overexpressed in solid tumours, such as breast, colorectal and ovarian cancer, which often correlated with malignancy and poor prognosis. Dual SRC/ABL kinase inhibitors (e.g. dasatinib, bosutinib) are already in clinical use for the treatment of chronic myeloid leukaemia. However, attempts to repurpose them for their SRC inhibition alone have so far failed in clinical trials. Several studies suggest that ABL kinase can act as a tumour suppressor in solid cancers and its inhibition has been linked to cardiotoxic events in patients. This complicates the use of SRC/ABL inhibitors in combination with other anti-cancer agents with cardiac side effects, such as chemotherapeutics, certain monoclonal antibodies and other kinase inhibitors; yet resistance to several of these drugs was found to involve the activation of SRC signalling pathways. Consequently, there is a clear need for more selective SRC inhibitors which have the potential to exhibit greater efficacy and fewer side effects than the ones currently available. The novel small molecule SRC inhibitor eCF506 has recently been discovered by the Innovative Therapeutics Lab at the University of Edinburgh 1. It exhibits nanomolar potency, thousand-fold selectivity for SRC over ABL kinase and superior drug-like properties compared to the current gold-standard SRC inhibitor dasatinib. This thesis continues the preclinical development of eCF506 by (i) investigating its potency against different cancers in in vitro and in vivo models, (ii) assessing its safety and pharmacokinetic properties and (iii) identifying a unique binding mode to SRC kinase.
Degree
thesis:*- Grantor dc:publisher
- The University of Edinburgh
- Year dc:date.issued
- 2020
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Temps, Carolin
- Advisors dc:contributor.advisor
-
- Unciti-Broceta, Asier
- Carragher, Neil
Subjects
dc:subject × 5Rights
- Language dc:language.iso
- en
Identifiers
dc:identifier.*- Identifier URI
- http://dx.doi.org/10.7488/era/279